SunMed is a leading advisor to Life Science companies ranging from those still in clinical stage to those with commercial products on the market. We bring value to all stages of transactions, from initiation and sourcing, through closing. Our primary focus is on cross boarder licensing. Our management team has over 30 years of experience successfully completing transactions.
After 10 years in the industry, we decided to alter direction. Now, we share our passion by helping others. Our ramp up process is designed to empower your team and outfit them with the tools they need to succeed. Talk to us today about how we can support your growth, reduce your corporate burn rate, and put you on a solid track to success and profit.
Our service includes a comprehensive consult to help identify gaps and opportunities, a comprehensive report that includes a project plan with timelines and milestones, a cost analysis, and a schedule. We also offer industry specific services that will help you get there quickly and smoothly. That’s how we ensure your success.
The right evaluation is key — that’s why when it comes to client selection, we’re choosy. We want to give each of you the time and guidance you deserve. Whether you’re seeking a strategic alliance with the right partner or a special skillset or tool, call us today. Together we’ll create and refine your plan for success. We didn’t get there alone. And neither will you.
Our pharmaceutical/biotechnology relationships are valuable in negotiating favorable licensing agreements for our clients. Many potential in-licensing companies are considering multiple products, and have challenges navigating the corporate “red tape” that often revolves around the capital requirements of in-licensing products. We help our clients understand the value proposition associated with each potential deal. It is in this way, that we are even considered value added to even an experienced business development team at a client company.
Each transaction is unique. In one situation, we might assist on getting the right process in place. In another, the financial details and valuation might be the key negotiating hurdle. SunMed management has experience navigating all obstacles to help achieve a successful outcome.
If you are you looking to diversifying your portfolio or pipeline, Sunmed has relationships with Universities that are looking to commercialize early stage products.? This can help you get access to the latest innovation. Given our global ( strong Asian ) presence we can introduce you to opportunities from all over the world. While the US remains the major source of healthcare innovation, countries such as Japan and China have made great strides as well. SunMed maintains excellent relationships all over the world.
SunMed will help maximize the value of your assets globally either on the buy side or sell side. It is in these circumstances that if you are looking for sources of non-dilutive capital to fund your clinical development or commercialize your product, we can be of assistance.
SunMed can help you license your product under terns that are favorable and assist with immediate cash needs. With a direct presence in Japan and other parts of the world with large markets, SunMed can be a one-stop partnering shop.. SunMed can help you for all territories at the same time. In addition, our services go beyond getting you the best financial terms. Additionally, SunMed can advise you on regulatory timelines, or how to optimize your CRO relationships to maximize your profit and reduce expenses. Finally, as is usually the case, utilizing our team’s local experience, we often have relationships with the decision makers. This can usually expedite the business development process.
In summary with our global presence, we can provide a number of services from the divestiture of an asset to strategic and financial transactions. Our contacts are located all over the world. Our process is seamless and well tested. We keep our clients in the loop at every step of the way, giving them an understanding of where things stand. We pride ourselves in a streamlined process, reduced legal red tape, and happy clients on both sides of the table.
Networking events for peer to peer interactions with Key Opinion Leaders in the Life Science space and Pharmaceutical industry.
Corporate Analyst
Small molecule drug that penetrates the blood-brain barrier and activates PKC enzymes, resulting in improved synaptic function, new synapse formation, repair of damaged synapses, and prevention of neuronal death in Alzheimer’s.
Neurology Phase 2 Product
Novel first-in-class drug with ground-breaking potential utilizing a unique delivery method to slow or stop the progression of Glaucoma and dry AMD - neurodegenerative diseases and leading causes of blindness.
Ophthalmology Phase 2 Product
Low cost universal insulin delivery system licensed form large pharma for initial 510K approval expected within 12 months.
Insulin Delivery System
Licensed device from University that creates Apoptosis in patients reducing inflammation in major organs and blood vessels
Apoptosis Device
Immuno resistant device holding stem cells, allowing them to produce insulin without triggering the body's T-Cell response
Artificial Pancreas Device
Reformulation of steroid for delayed release in the intestinal tract thus reducing prototypical side effect profile of orally administered steriods
Small Molecule for IBS and IBD
Reformulation of topical into oral formulation for various blood cancers
Oncology Phase 3 Product